Skip to main content
Context Therapeutics Inc. logo

Context Therapeutics Inc. — Investor Relations & Filings

Ticker · CNTX ISIN · US21077P1084 LEI · 549300U5ISIWCBXD6W77 US Manufacturing
Open in API
Filings indexed 277 across all filing types
Latest filing 2026-05-18 Regulatory Filings
Country US United States of America
Listing US CNTX

About Context Therapeutics Inc.

https://www.contexttherapeutics.com/

Context Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to advancing treatments for solid tumors. The company develops next-generation T cell engaging (TCE) bispecific antibody therapies designed to harness the patient's immune system for targeted cancer eradication. Its pipeline features innovative immunotherapeutic solutions for difficult-to-treat solid tumors. Key portfolio highlights include CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody; CT-95, an avidity-enhanced mesothelin (MSLN) x CD3 bispecific antibody; and CT-202, a dual pH-dependent Nectin-4 x CD3 bispecific antibody.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 70% confidence The text is a U.S. SEC Form 8-K “Current Report” disclosing the entry into a material definitive agreement (license amendment) and Regulation FD disclosure via a press release. It is not an earnings release, interim/annual report, management discussion, M&A filing, financing notice, or ESG report. No specialized category fits contract amendments in Form 8-K, so it falls under the general regulatory announcement/fallback category.
2026-05-18 English
ARS - Context Therapeutics Inc. (0001842952) (Filer)
Annual Report
2026-04-28 English
8-K - Context Therapeutics Inc. (0001842952) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 2, 2026. It announces that the FDA has granted Fast Track designation to a drug candidate, CTIM-76. The document includes a press release as an exhibit and states that the information is being furnished and not filed, indicating it is an announcement rather than a detailed report. The content is a regulatory announcement about a material event affecting the company, typical of a Regulatory Filing (RNS). The document length is 4142 characters, which is relatively short and consistent with an announcement rather than a full report. There are no financial statements or detailed financial data included. Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-04-02 English
S-8 - Context Therapeutics Inc. (0001842952) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form S-8 filing, which is a registration statement for securities to be offered under employee benefit plans. It includes a calculation of the filing fee table related to newly registered securities, stock options, and shares reserved under a long-term incentive plan. The content is regulatory in nature, related to securities registration and fee calculation, and does not contain financial statements, management discussion, or earnings data. It is not an annual report, earnings release, or any other financial report type. Given the nature and length (2516 characters), it is a regulatory filing related to securities registration. Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-03-23 English
8-K - CONTEXT THERAPEUTICS INC. (0001842952) (Filer)
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 24, 2026. It reports on a legal event involving a stipulation and proposed consent judgment related to a stockholder class action complaint and changes to the company's charter provisions regarding director terms and removal. It also discusses the upcoming 2026 annual meeting of stockholders and procedural details for stockholder proposals and nominations. The document does not contain financial statements or detailed financial data, nor is it a transcript, presentation, or proxy solicitation. It is primarily a regulatory announcement of a legal and governance event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2026-02-27 English
4 - CONTEXT THERAPEUTICS INC. (0001842952) (Filer)
Director's Dealing
2026-02-23 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.